Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: February 9, 2023

Details for Patent: 10,028,937

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 10,028,937 protect, and when does it expire?

Patent 10,028,937 protects MAVYRET and is included in two NDAs.

Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has two hundred and seventy patent family members in forty-four countries.

Summary for Patent: 10,028,937
Title:Anti-viral compounds
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Inventor(s): Bellizzi; Mary E. (Missoula, MT), Betebenner; David A. (Grayslake, IL), Califano; Jean-Christophe C. (Whitefish Bay, WI), Carroll; William A. (Evanston, IL), Caspi; Daniel D. (Evanston, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Flentge; Charles A. (Pittsburgh, PA), Gao; Yi (Vernon Hills, IL), Hutchins; Charles W. (Green Oaks, IL), Hutchinson; Douglas K. (Newton, CT), Jinkerson; Tammie K. (Pleasant Prairie, WI), Kati; Warren M. (Gurnee, IL), Keddy; Ryan G. (Beach Park, CA), Krueger; Allan C. (Gurnee, IL), Li; Wenke (Gurnee, CN), Liu; Dachun (Vernon Hills, CN), Maring; Clarence J. (Palatine, IL), Matulenko; Mark A. (Libertyville, IL), Motter; Christopher E. (Oak Creek, WI), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Sarris; Kathy (Mundelein, IL), Tufano; Michael D. (Chicago, IL), Wagaw; Seble H. (Lake Bluff, IL), Wagner; Rolf (Antioch, IL), Woller; Kevin R. (Antioch, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:15/434,789
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,028,937

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.